Mayo Clinic Comprehensive Cancer Center experts highlight breast cancer research that may reduce or eliminate the need for chemotherapy and endocrine treatments and may allow for shorter and less ...
Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...